INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future
Executive Summary
Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.
You may also be interested in...
Alvogen builds on Asian Dream with $187m acquisition
US-based generics company Alvogen has shelled out $187m for its third major acquisition in Asia in two years, scooping up South Korea's Dream Pharma.
Alvogen builds $250m biosimilars plant in Iceland
Alvotech, an Iceland-based sister company of the privately owned US generics firm Alvogen, is to invest $250m in a biosimilars development and manufacturing facility in Reykjavik, Iceland. The plant will produce biosimilar monoclonal antibodies for marketing by Alvogen, which currently markets biosimilars in some parts of the world through alliances with other firms, including Hospira.
Alvogen opens office in Bucharest
The US-based pharmaceutical company Alvogen has established a subsidiary, Alvogen Romania, and opened an office in Bucharest. Laurentiu Scheusan, former manager of Actavis's local operations in Hungary, has been appointed managing director of the new company.